GLP-1 Therapies Newsletter
Issue #62November 9, 20267 studies

Ozempic cut prolactin levels in healthy men — and nobody's sure why

GLP-1 drugs keep doing things nobody asked them to do.

This week's research adds prolactin, reward circuits, and ventricular heartbeat blips to an already crowded list of unexpected effects.

GLP-1 Drug Quietly Lowered a Sex Hormone — And It Wasn't the Goal 🧪

  • A small crossover trial gave 24 healthy, normal-weight men four weeks of dulaglutide (a weekly GLP-1 injection) or placebo. Prolactin — a hormone involved in sexual function — dropped by about 31 units on the drug and rose by 45 units on placebo. That gap was statistically meaningful.
  • More than half the participants (13 of 24) showed parallel drops in both prolactin and appetite scores, hinting the two effects might share a mechanism. But prolactin levels had no detectable link to sexual desire, so the hormone change didn't translate into the mood shift researchers were originally hunting for.
  • The trial was designed to test whether dulaglutide changed sexual desire — it didn't, at least not through prolactin. What it found instead was an unexpected hormonal signal that points toward broader effects on the brain's endocrine control systems.

Why it matters: Prolactin is regulated by dopamine pathways in the brain. If GLP-1 drugs are nudging those pathways, the implications stretch well beyond appetite — into mood, motivation, and hormones we haven't started measuring yet.

🔗 Journal of neuroendocrinology Randomized Controlled Trial 🗓️ Nov 5

Key Findings

Surgery Still Wins on Diabetes, but GLP-1 Drugs Are Closing the Gap 🏥

  • A nationwide cohort of 379,858 patients compared metabolic bariatric surgery against incretin-based drug therapy. Surgery produced stronger cardiovascular and diabetes outcomes overall, but the gap narrowed considerably as newer, more potent drug options entered the picture.
  • The study underscores that neither approach is universally superior — patient phenotype, risk tolerance, and access all shape which route makes sense.
💡 Surgery leads on outcomes, but the drug-versus-scalpel gap is shrinking fast.
🎖️ Top 10% journal 🔗 The British journal of surgery Comparative Study 🗓️ Nov 3

Semaglutide Is Linked to an Irregular Heartbeat Signal Worth Watching ⚡

  • A disproportionality analysis across two major pharmacovigilance databases — VigiBase and the FDA's adverse event system — found that premature ventricular contractions (extra heartbeats) were consistently over-reported among semaglutide users. It was the only cardiac rhythm term that cleared the signal threshold in both databases.
  • Spontaneous reporting data can't establish causation or tell us how often this actually happens. But the consistency across two independent systems makes it worth prospective investigation with real electrocardiographic monitoring.
💡 A consistent cardiac rhythm signal in two databases — not proof, but not ignorable.
Top 30% journal 🔗 Naunyn-Schmiedeberg's archives of pharmacology Journal Article 🗓️ Nov 6

Muscle Loss on GLP-1 Drugs Probably Isn't the Drug's Fault Directly 💪

  • Researchers treated primary human muscle cells from older adults with semaglutide or a GIP peptide and looked for signs of muscle breakdown, impaired growth, or metabolic damage. Neither drug caused meaningful atrophy, inflammation, or impaired muscle formation at the cellular level.
  • The lean mass loss seen in clinical trials is likely an indirect consequence of eating less and moving less — not a direct pharmacological attack on muscle tissue. That distinction matters enormously for how clinicians counsel older patients.
💡 GLP-1 drugs don't seem to directly harm muscle cells — the loss goes elsewhere.
🎖️ Top 10% journal 🔗 GeroScience Journal Article 🗓️ Nov 4

GLP-1 Drugs Are Associated With Lower Alcohol Use Disorder Risk 🍺

  • A target trial emulation compared adults with type 2 diabetes starting semaglutide or tirzepatide against those starting SGLT2 inhibitors. Both GLP-1-based drugs were associated with a lower incidence of clinically recorded alcohol use disorder.
  • This is observational, not a controlled experiment, so confounding is possible. But it adds real-world weight to the biological hypothesis that GLP-1 receptor activation dampens reward-driven craving — not just for food.
💡 Real-world data links GLP-1 drugs to lower alcohol disorder rates in diabetes patients.
🔗 Diabetes, obesity & metabolism Journal Article 🗓️ Nov 3

Nearly Half of GLP-1 Users Bought From High-Risk Sources 🛒

  • A survey of 242 people who currently use, previously used, or were considering GLP-1 drugs found that 46% of active users reported purchasing from personal networks or individual online sellers — not pharmacies or clinicians.
  • Social media heavily shaped perceptions: over half said online content influenced how they think about these drugs. Posts featuring branded packaging and accredited pharmacy sellers were most trusted, suggesting that how products are displayed online meaningfully shapes purchasing behavior.
💡 Nearly half of GLP-1 users sourced drugs outside safe channels — social media drove it.
Top 30% journal 🔗 PloS one Journal Article 🗓️ Nov 4

The Thyroid Cancer Warning on GLP-1 Drugs May No Longer Be Justified 🦋

  • A comprehensive review of preclinical and human data argues that the FDA boxed warning linking GLP-1 drugs to thyroid C-cell cancer risk — based on rodent studies — does not hold up in primates or in clinical trial and registry data. Rodents have more C-cells, more GLP-1 receptors in the thyroid, and a different cancer pathway than humans.
  • U.S. medullary thyroid cancer trends since 2005, when the first GLP-1 drug launched, have actually shown a declining relative share. The authors conclude the warning is no longer scientifically warranted.
💡 Rodent-derived thyroid cancer warning may not apply to humans, review concludes.
🥇 Top 1% journal 🔗 Endocrine reviews Journal Article 🗓️ Nov 5

Implications

GLP-1 drugs are now touching prolactin, reward circuits, cardiac rhythm, and thyroid cancer risk debates all in the same week. The clearest unresolved tension: if these drugs reshape dopamine signaling broadly, we still have no framework for predicting which patients will benefit from that — and which won't.

Studies in this issue

Primary sources used for this newsletter.

  1. Semaglutide and Tirzepatide linked to alcohol-related outcomes in type 2 diabetes
    key findingDiabetes, obesity & metabolism2026-11-03PMID 42977546
  2. Analysis of Extra Heartbeats Reported with Semaglutide in Global and US Safety Databases
    key findingNaunyn-Schmiedeberg's archives of pharmacology2026-11-06PMID 42993217